{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:06:35Z","timestamp":1761102395174,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Fulbright-Garc\u00eda Robles"},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["U01-CA-199335"],"award-info":[{"award-number":["U01-CA-199335"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40273-019-00859-5","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T02:02:26Z","timestamp":1574388146000},"page":"285-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-1172","authenticated-orcid":false,"given":"Fernando","family":"Alarid-Escudero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen M.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"859_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/acprof:oso\/9780190492939.003.0005","volume-title":"Cost-Effectiveness in Health and Medicine","author":"Karen M. Kuntz","year":"2016","unstructured":"Kuntz KM, Russell LB, Owens DK, Sanders GD, Trikalinos TA, Salomon JA. Decision models in cost-effectiveness analysis. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness Heal Med. Second. New York: Oxford University Press; 2017. p. 105\u201336."},{"key":"859_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/0272989X9501500209","volume":"15","author":"KM Kuntz","year":"1995","unstructured":"Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling. Med Decis Mak. 1995;15:158\u201369.","journal-title":"Med Decis Mak."},{"key":"859_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1177\/0272989X09340238","volume":"29","author":"TGK Bentley","year":"2009","unstructured":"Bentley TGK, Weinstein MC, Kuntz KM. Effects of categorizing continuous variables in decision-analytic models. Med Decis Mak. 2009;29:549\u201356.","journal-title":"Med Decis Mak."},{"key":"859_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1177\/0272989X10363480","volume":"30","author":"TGK Bentley","year":"2010","unstructured":"Bentley TGK, Kuntz KM, Ringel JS. Bias associated with failing to incorporate dependence on event history in Markov models. Med Decis Mak. 2010;30:651\u201360.","journal-title":"Med Decis Mak."},{"key":"859_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/0272989X03023003005","volume":"23","author":"SJ Goldie","year":"2010","unstructured":"Goldie SJ, Kuntz KM. A potential error in evaluating cancer screening: a comparison of 2 approaches for modeling unerlying disease progression. Med Decis Mak. 2010;23:232\u201341.","journal-title":"Med Decis Mak."},{"key":"859_CR6","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"MR Gold","year":"1996","unstructured":"Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996."},{"key":"859_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"MC Weinstein","year":"2003","unstructured":"Weinstein MC, O\u2019Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9\u201317.","journal-title":"Value Health."},{"key":"859_CR8","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 [Internet]. London, UK; 2013. p. 1\u201393. Available from: http:\/\/www.nice.org.uk\/article\/pmg9\/resources\/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf."},{"key":"859_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrclinonc.2011.217","volume":"9","author":"KB Blagoev","year":"2012","unstructured":"Blagoev KB, Wilkerson J, Fojo T. Hazard ratios in cancer clinical trials\u2014a primer. Nat Rev Clin Oncol. 2012;9:178\u201383.","journal-title":"Nat Rev Clin Oncol."},{"key":"859_CR10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Models and life-tables regression. J R Stat Soc. 1972;34:187\u2013220.","journal-title":"J R Stat Soc."},{"key":"859_CR11","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1128\/AAC.48.8.2787-2792.2004","volume":"48","author":"SL Spruance","year":"2004","unstructured":"Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48:2787\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"859_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1524-4733.2005.00045.x","volume":"8","author":"SD Ramsey","year":"2005","unstructured":"Ramsey SD, Willke R, Briggs AH, Brown RE, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force Report. Value Health. 2005;8:521\u201333.","journal-title":"Value Health."},{"key":"859_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","volume":"18","author":"SD Ramsey","year":"2015","unstructured":"Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II\u2014an ISPOR Good Research Practices Task Force Report. Value Health. 2015;18:161\u201372.","journal-title":"Value Health."},{"volume-title":"Cost-Effectiveness in Health and Medicine","year":"2016","key":"859_CR14","unstructured":"Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. Second. New York: Oxford University Press, Incorporated; 2017."},{"key":"859_CR15","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006."},{"key":"859_CR16","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies. 3rd ed. 2006."},{"key":"859_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: Inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33:743\u201354.","journal-title":"Med Decis Mak."},{"key":"859_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Mak. 2012;32:667\u201377.","journal-title":"Med Decis Mak."},{"key":"859_CR19","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.","edition":"3"},{"issue":"12 Suppl","key":"859_CR20","first-page":"DS99","volume":"34","author":"B O\u2019Brien","year":"1996","unstructured":"O\u2019Brien B. Economic evaluation of pharmaceuticals: Frankenstein\u2019s monster or vampire of trials? Med Care. 1996;34(12 Suppl):DS99\u2013108.","journal-title":"Med Care"},{"key":"859_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/sim.6375","volume":"34","author":"T Benaglia","year":"2014","unstructured":"Benaglia T, Jackson CH, Sharples LD. Survival extrapolation in the presence of cause specific hazards. Stat Med. 2014;34:796\u2013811.","journal-title":"Stat Med"},{"key":"859_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0272989X16639900","volume":"37","author":"C Jackson","year":"2017","unstructured":"Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A, et al. Extrapolating survival from randomized trials using external data: a review of methods. Med Decis Mak. 2017;37:377\u201390.","journal-title":"Med Decis Mak."},{"key":"859_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Briggs AH, Mackay DF. Estimation of survival probabilities for use in cost-effectiveness analysis: a comparison of a multi-state modelling survival analysis approach with partitioned survival and Markov decision-analytic modelling. Med Decis Mak. 2017;37:427\u201339.","journal-title":"Med Decis Mak."},{"key":"859_CR24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oso\/9780192631770.003.0007","volume-title":"Econ eval heal care merging theory with pract","author":"KM Kuntz","year":"2001","unstructured":"Kuntz KM, Weinstein MC. Modelling in economic evaluation. In: Drummond MF, McGuire A, editors. Econ eval heal care merging theory with pract. 2nd ed. New York: Oxford University Press; 2001. p. 141\u201371.","edition":"2"},{"issue":"7","key":"859_CR25","first-page":"1","volume":"62","author":"E Arias","year":"2014","unstructured":"Arias E. United States Life Tables, 2009. Nat Vital Stat Rep. 2014;62(7):1\u201363.","journal-title":"Nat Vital Stat Rep"},{"key":"859_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/02789X02022003004","volume":"22","author":"KM Kuntz","year":"2002","unstructured":"Kuntz KM, Goldie SJ. Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias. Med Decis Mak. 2002;22:218\u201327.","journal-title":"Med Decis Mak."},{"key":"859_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak. 1993;13:322\u201338.","journal-title":"Med Decis Mak."},{"key":"859_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0272989X8300300403","volume":"3","author":"JR Beck","year":"1983","unstructured":"Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Mak. 1983;3:419\u201358.","journal-title":"Med Decis Mak."},{"key":"859_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.22237\/jmasm\/1509494520","volume":"16","author":"M Harwell","year":"2017","unstructured":"Harwell M, Kohli N, Peralta Y. Experimental design and data analysis in computer simulation studies in the behavioral sciences. J Mod Appl Stat Methods. 2017;16:3\u201328.","journal-title":"J Mod Appl Stat Methods."},{"key":"859_CR30","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/sim.8086","volume":"38","author":"TP Morris","year":"2019","unstructured":"Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical methods. Stat Med. 2019;38:2074\u2013102.","journal-title":"Stat Med"},{"key":"859_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJM198008073030607","volume":"303","author":"M Mirowski","year":"1980","unstructured":"Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303:322\u20134.","journal-title":"N Engl J Med"},{"key":"859_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","volume":"346","author":"AJ Moss","year":"2002","unstructured":"Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877\u201383.","journal-title":"N Engl J Med"},{"key":"859_CR33","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMsa051989","volume":"353","author":"GD Sanders","year":"2005","unstructured":"Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471\u201380.","journal-title":"N Engl J Med"},{"key":"859_CR34","first-page":"1","volume":"19","author":"Technology Evaluation Center","year":"2004","unstructured":"Technology Evaluation Center. Special report: cost-effectiveness of implantable cardioverter-defibrillators in a MADIT-II population. Assess Progr. 2004;19:1\u20132.","journal-title":"Assess Progr."},{"key":"859_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"DG Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Mak. 1993;13:89\u2013102.","journal-title":"Med Decis Mak."},{"key":"859_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-126-1-199701010-00001","volume":"126","author":"DK Owens","year":"1997","unstructured":"Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126:1\u201312.","journal-title":"Ann Intern Med"},{"key":"859_CR37","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1161\/01.CIR.103.10.1416","volume":"103","author":"BJ O\u2019Brien","year":"2001","unstructured":"O\u2019Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103:1416\u201321.","journal-title":"Circulation"},{"key":"859_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0272989X16686559","volume":"37","author":"H Jalal","year":"2017","unstructured":"Jalal H, Pechlivanoglou P, Krijkamp E, Alarid-Escudero F, Enns EA, Hunink MGM. An overview of R in health decision sciences. Med Decis Mak. 2017;37:735\u201346.","journal-title":"Med Decis Mak."},{"key":"859_CR39","first-page":"1929","volume":"6","author":"GD Sanders","year":"2015","unstructured":"Sanders GD, Owens DK, Hlatky MA. Potential cost-effectiveness of wearable cardioverter-defibrillator early post myocardial infarction. Innov Card Rhythm Manag. 2015;6:1929\u201340.","journal-title":"Innov Card Rhythm Manag."},{"key":"859_CR40","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1093\/europace\/euq329","volume":"12","author":"DAMJ Theuns","year":"2010","unstructured":"Theuns DAMJ, Smith T, Hunink MGM, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12:1564\u201370.","journal-title":"Europace."},{"key":"859_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/eurheartj\/ehs090","volume":"34","author":"T Smith","year":"2013","unstructured":"Smith T, Jordaens L, Theuns DAMJ, Van Dessel PF, Wilde AA, Myriam Hunink MG. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J. 2013;34:211\u20139.","journal-title":"Eur Heart J"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00859-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00859-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00859-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T14:43:51Z","timestamp":1722091431000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00859-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00859-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2019,11,22]]},"assertion":[{"value":"22 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr Alarid-Escudero was supported by a grant from Fulbright-Garc\u00eda Robles and the National Council of Science and Technology of Mexico (CONACYT) as part of Dr Alarid-Escudero\u2019s doctoral program. Drs Kuntz and Alarid-Escudero were supported by a grant from the National Cancer Institute (U01-CA-199335) as part of the Cancer Intervention and Surveillance Modeling Network (CISNET). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding agencies had no role in the design of the study, interpretation of results, or writing of the manuscript. The funding agreement ensured the authors\u2019 independence in designing the study, interpreting the data, writing, and publishing the report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding\/support"}},{"value":"FA-E reports no conflicts of interest. KMK reports no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data and statistical code are provided in the <tt>dsHR<\/tt>\u00a0R package hosted in the\u00a0GitHub repository. The version of <tt>dsHR<\/tt> released in this article is available at.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}